Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis

Background & Aims: We have shown previously that mycophenolate mofetil (MMF) might be used as first-line treatment instead of azathioprine (AZA) in individuals with autoimmune hepatitis (AIH). Herein, we present our long-term prospective data on response and outcome after first-line therapy...

Full description

Bibliographic Details
Published in:	JHEP Reports
Main Authors:	George N. Dalekos, Pinelopi Arvaniti, Nikolaos K. Gatselis, Stella Gabeta, Anna Samakidou, George Giannoulis, Eirini Rigopoulou, George K. Koukoulis, Kalliopi Zachou
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Subjects:	Autoimmune hepatitis Mycophenolate mofetil Azathioprine Outcome Survival
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555922001732

Similar Items

Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis
by: Amani M. Ali, et al.
Published: (2025-08-01)

Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01)

A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study
by: Siriorn Sukanjanapong, et al.
Published: (2019-12-01)

A Case of Repeat Kidney Transplant Intolerant to Multiple First-line Immunosuppressive Agents Mycophenolate Mofetil, Azathioprine, and Calcineurin Inhibitors
by: Puneet Arora, et al.
Published: (2024-12-01)

Comparative efficacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis
by: R. S. Rud, et al.
Published: (2021-12-01)

Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis
by: Mirjam Kolev, et al.
Published: (2022-01-01)

Granulomatosis with polyangiitis – therapeutic challenge
by: Dorota Szydlarska, et al.
Published: (2016-02-01)

Mycophenolate Mofetil and Clostridium difficile-associated Colitis
by: A. I. Dolgushina, et al.
Published: (2021-12-01)

Therapeutic effects of topical Mycophenolate mofetil on hydroquinone-induced depigmentation in Guinea pigs and mice
by: Yuan Guo, et al.
Published: (2025-12-01)

Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01)

Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies
by: Corrado Campochiaro, et al.
Published: (2024-04-01)

Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?: A mini-review
by: Alice Tung Wan Song, et al.

Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil
by: Mustafa Çakan, et al.
Published: (2019-10-01)

Mycophenolate Mofetil-Induced Segmental Colitis Mimicking Ischemic Colitis
by: Kevin Johal, et al.
Published: (2014-03-01)

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
by: Yichen Jia, et al.
Published: (2018-07-01)

Acute pancreatitis induced by mycophenolate mofetil in a kidney transplant patient
by: Einollahi Behzad, et al.
Published: (2015-04-01)

Duodenal villous atrophy caused by Mycophenolate Mofetil in patients with solid organ transplantation: case report
by: Giuston Mendoza-Chuctaya, et al.
Published: (2016-03-01)

Pharmacokinetics of mycophenolic acid and its effect on CD4+ and CD8+ T cells after oral administration of mycophenolate mofetil to healthy cats
by: Jennifer E. Slovak, et al.
Published: (2019-09-01)

Evaluation of neutropenia secondary to mycophenolate mofetil associated with valganciclovir in liver transplant patients
by: Alejandro Ferrer-Machín, et al.
Published: (2021-03-01)

Mycophenolate mofetil-related colitis in a paediatric patient after kidney transplant
by: Natalia Oleksik, et al.
Published: (2022-10-01)

Mycophenolate mofetil in giant cell arteritis
by: Anne Pankow, et al.
Published: (2023-11-01)

The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: A concise review
by: Roger D. Soloway, et al.
Published: (2007-10-01)

Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies
by: C Bandelier
Published: (2009-01-01)

Mycophenolate mofetil in the treatment of non-renal manifestations of systemic lupus erythematosus: recent insights
by: Ali SAHIN
Published: (2010-05-01)

Response to mycophenolate mofetil therapy in the patient with severe systemic lupus erythematosus
by: Božić-Majstorović Ljubinka, et al.
Published: (2016-01-01)

Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
by: Domenico Paolo Emanuele Margiotta, et al.
Published: (2018-03-01)

Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
by: Jun Zhang, et al.
Published: (2018-08-01)

Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease
by: TONG ZHANG, et al.
Published: (2009-01-01)

Mycophenolate mofetil versus cyclophosphamide for idiopathic membranous nephropathy; a double blind and randomized clinical trial
by: Fatemeh Hayati, et al.
Published: (2019-04-01)

Protective effect of melatonin and mycophenolate mofetil against nephrotoxicity induced by tacrolimus in wistar rats
by: Suleyman KOC, et al.
Published: (2021-11-01)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
by: Bing Du, et al.
Published: (2017-07-01)

Efficacy of mycophenolate mofetil combined with topical 0.05% tacrolimus in high-risk keratoplasty: 1-year cohort study
by: Jin-Yu Zhang, et al.
Published: (2024-12-01)

Current and emerging treatment options in the management of lupus
by: Jordan N, et al.
Published: (2016-03-01)

Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using <i>Ex Vivo</i> T Cell Function Assays
by: Aliede E. in ’t Veld, et al.
Published: (2023-05-01)

Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study
by: Alexandra Mazo, et al.
Published: (2024-03-01)

Pharmacological Therapeutic Monitoring of Mycophenolate Mofetil (MMF) in Renal Transplant Recipients.
by: Mohamed Habib BELMAHI, et al.
Published: (2025-03-01)

STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
by: O A Koneva, et al.
Published: (2011-08-01)

Sex-Specific Responses to Tacrolimus and Mycophenolate Mofetil in Spontaneously Hypertensive Rats
by: Rodrigo Oscar Marañón, et al.
Published: (2023-11-01)

Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients
by: Siqin Sun, et al.
Published: (2024-12-01)

Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report
by: Chang Jiang, et al.
Published: (2025-02-01)